Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells

Journal of Immunology

Volumn 189, Issue 4, 2012, Pages 1708-1716

  Bak, S Peter ^a   Barnkob, MikeStein ^a   Bai, Ailin ^a,c   Higham, Eileen M ^a,b,d   Wittrup, K Dane ^a,b   Chen, Jianzhu ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c AVEO ONCOLOGY   (United States)

^d MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD137 LIGAND; CD70 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE FUNCTION; MALE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INTERACTION; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD70; ANTIGENS, CD80; ANTIGENS, CD86; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PROSTATIC NEOPLASMS;

EID: 84864808097     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201271     Document Type: Article

References (37)

1. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308. (Pubitemid 351430867)
2. Gulley, J. L., and C. G. Drake. 2011. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin. Cancer Res. 17: 3884-3891.
3. Sharpe, A. H. 2009. Mechanisms of costimulation. Immunol. Rev. 229: 5-11.
4. Fife, B. T., and J. A. Bluestone. 2008. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224: 166-182.
5. Pilon-Thomas, S., A. Mackay, N. Vohra, and J. J. Mulé. 2010. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184: 3442-3449.
6. Chen, L., P. McGowan, S. Ashe, J. V. Johnston, I. Hellström, and K. E. Hellström. 1994. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 54: 5420-5423. (Pubitemid 24336035)
7. Antonia, S. J., J. Seigne, J. Diaz, C. Muro-Cacho, M. Extermann, M. J. Farmelo, M. Friberg, M. Alsarraj, J. J. Mahany, J. Pow-Sang, et al. 2002. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167: 1995-2000. (Pubitemid 34309645)
8. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68. (Pubitemid 40563164)
9. Arens, R., K. Schepers, M. A. Nolte, M. F. van Oosterwijk, R. A. van Lier, T. N. Schumacher, and M. H. van Oers. 2004. Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J. Exp. Med. 199: 1595-1605. (Pubitemid 38780414)
10. May, K. F., Jr., L. Chen, P. Zheng, and Y. Liu. 2002. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62: 3459-3465. (Pubitemid 34651393)
11. Bai, A., E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen. 2008. Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Natl. Acad. Sci. USA 105: 13003-13008.
12. Olurinde, M. O., C. H. Shen, A. Drake, A. Bai, and J. Chen. 2011. Persistence of tumor-infiltrating CD8 T cells is tumor-dependent but antigen-independent. Cell Mol. Immunol. 8: 415-423.
13. Higham, E. M., C. H. Shen, K. D. Wittrup, and J. Chen. 2010. Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model. J. Immunol. 184: 5954-5958.
14. Van Deusen, K. E., R. Rajapakse, and T. N. Bullock. 2010. CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses. J. Leukoc. Biol. 87: 477-485.
15. Sakuishi, K., P. Jayaraman, S. M. Behar, A. C. Anderson, and V. K. Kuchroo. 2011. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32: 345-349.
16. Woo, S. R., M. E. Turnis, M. V. Goldberg, J. Bankoti, M. Selby, C. J. Nirschl, M. L. Bettini, D. M. Gravano, P. Vogel, C. L. Liu, et al. 2012. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72: 917-927.
17. Zhou, P., X. Zheng, H. Zhang, Y. Liu, and P. Zheng. 2009. B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer. Clin. Cancer Res. 15: 960-970.
18. Fuse, S., W. Zhang, and E. J. Usherwood. 2008. Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J. Immunol. 180: 1148-1157.
19. Habib-Agahi, M., T. T. Phan, and P. F. Searle. 2007. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int. Immunol. 19: 1383-1394. (Pubitemid 350131344)
20. Shuford, W. W., K. Klussman, D. D. Tritchler, D. T. Loo, J. Chalupny, A. W. Siadak, T. J. Brown, J. Emswiler, H. Raecho, C. P. Larsen, et al. 1997. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55. (Pubitemid 27304846)
21. Lee, H.W., S. J. Park, B. K. Choi, H. H. Kim, K. O. Nam, and B. S. Kwon. 2002. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J. Immunol. 169: 4882-4888.
22. Schildknecht, A., I. Miescher, H. Yagita, and M. van den Broek. 2007. Priming of CD8+ T cell responses by pathogens typically depends on CD70-mediated interactions with dendritic cells. Eur. J. Immunol. 37: 716-728. (Pubitemid 46916938)
23. Tesselaar, K., Y. Xiao, R. Arens, G. M. van Schijndel, D. H. Schuurhuis, R. E. Mebius, J. Borst, and R. A. van Lier. 2003. Expression of the murine CD27 ligand CD70 in vitro and in vivo. J. Immunol. 170: 33-40. (Pubitemid 36026120)
24. Seko, Y., N. Takahashi, H. Oshima, O. Shimozato, H. Akiba, K. Takeda, T. Kobata, H. Yagita, K. Okumura, M. Azuma, and R. Nagai. 2001. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3. J. Pathol. 195: 593-603. (Pubitemid 34030798)
25. Kurlander, R. J., D. M. Ellison, and J. Hall. 1984. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J. Immunol. 133: 855-862. (Pubitemid 14093480)
26. Keller, A. M., A. Schildknecht, Y. Xiao, M. van den Broek, and J. Borst. 2008. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29: 934-946.
27. Bertram, E. M., P. Lau, and T. H. Watts. 2002. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J. Immunol. 168: 3777-3785. (Pubitemid 34298377)
28. Keller, A. M., Y. Xiao, V. Peperzak, S. H. Naik, and J. Borst. 2009. Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting. Blood 113: 5167-5175.
29. Roberts, D. J., N. A. Franklin, L. M. Kingeter, H. Yagita, A. L. Tutt, M. J. Glennie, and T. N. Bullock. 2010. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J. Immunother. 33: 769-779.
30. Shafer-Weaver, K. A., S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, and A. A. Hurwitz. 2009. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 69: 6256-6264.
31. Bullock, T. N., and H. Yagita. 2005. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J. Immunol. 174: 710-717. (Pubitemid 40094264)
32. Hochweller, K., and S. M. Anderton. 2005. Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity in vivo. Eur. J. Immunol. 35: 1086-1096. (Pubitemid 40542215)
33. Fourcade, J., Z. Sun, M. Benallaoua, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, V. Kuchroo, and H. M. Zarour. 2010. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207: 2175-2186.
34. Sakuishi, K., L. Apetoh, J. M. Sullivan, B. R. Blazar, V. K. Kuchroo, and A. C. Anderson. 2010. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207: 2187-2194.
35. Blackburn, S. D., A. Crawford, H. Shin, A. Polley, G. J. Freeman, and E. J. Wherry. 2010. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. J. Virol. 84: 2078-2089.
36. Rosenblatt, J., B. Glotzbecker, H. Mills, B. Vasir, D. Tzachanis, J. D. Levine, R. M. Joyce, K. Wellenstein, W. Keefe, M. Schickler, et al. 2011. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34: 409-418.
37. Fourcade, J., Z. Sun, O. Pagliano, P. Guillaume, I. F. Luescher, C. Sander, J. M. Kirkwood, D. Olive, V. Kuchroo, and H. M. Zarour. 2012. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor micro-environment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72: 887-896.